Tue, Jul 29, 2014, 9:30 AM EDT - U.S. Markets close in 6 hrs 30 mins

Recent

% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • bohemianclubman bohemianclubman Nov 20, 2012 1:30 PM Flag

    The growing incidence of NTM

    It seems as though the nearly 8% annual growth of NTM is somewhat of a mystery. It is also the chief reason that NIH has taken on an active role to find solutions. There is a relatively new website called NTM News, not to be confused with NTM Info and Research. The author is convinced that COPD medications CAUSE NTM.

    Here is what he says:

    Today, a new article came to my inbox (I subscribe to various sources, always seeking new information and research on NTM disease). Entitled, "Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis" it demonstrated that inhaled corticosteroid (ICS) therapy for chronic obstructive pulmonary disease is a STRONG RISK FACTOR for NTM!

    Symbicort and Advair have annual sales in the range of 7 Billion. If the author of NTM News is correct (and I'm not saying he is) NTM is going to become a much bigger problem.

    One of the next market moving pieces of news may well be the in vitro study of arikace vs. NTM which Lewis mentioned at the Lazard conference.

    In vitro we’ve not published the date yet but we will be doing so we showed great efficacy against NTM

    Perhaps this data will be released before the Openheimer conference in early December.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • By bohemianclubman.Nov 20, 2012 1:30 PM.Permalink

      It seems as though the nearly 8% annual growth of NTM is somewhat of a mystery. It is also the chief reason that NIH has taken on an active role to find solutions. There is a relatively new website called NTM News, not to be confused with NTM Info and Research. The author is convinced that COPD medications CAUSE NTM.

      Here is what he says:

      Today, a new article came to my inbox (I subscribe to various sources, always seeking new information and research on NTM disease). Entitled, "Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis" it demonstrated that inhaled corticosteroid (ICS) therapy for chronic obstructive pulmonary disease is a STRONG RISK FACTOR for NTM!

      Symbicort and Advair have annual sales in the range of 7 Billion. If the author of NTM News is correct (and I'm not saying he is) NTM is going to become a much bigger problem.

      One of the next market moving pieces of news may well be the in vitro study of arikace vs. NTM which Lewis mentioned at the Lazard conference.

      In vitro we’ve not published the date yet but we will be doing so we showed great efficacy against NTM

      Perhaps this data will be released before the Openheimer conference in early December.

    • I'd rather forgotten about NTM Bo having heard that Insmed was sitting on Arikace Phase II data for an unmet medical need afflicting 200,000 patients in the US alone.

      But fwiw I found the following quite by accident recently -

      "MDR-TB vs NTM

      Started by Amy Leitman on 09 Oct 2012

      I work for an organization that is specifically concerned with pulmonary nontuberculous mycobacterial disease (NTM). We are hearing reports from several countries that they are finding a signifcant amount of their MDR-TB cases are, in fact, pulmonary NTM.

      Working with the University of Miami, we have launched a pilot project to gather epidemiolgical data regarding this disease."

      I still think the big opportunity here is in fact NTM's brother - TB. Specifically MDR-TB.

      Amikacin kills Mycobacteria. I see this as simply a question of whether or not Arikace therapy is capable of delivering the Amikacin to the pulmonary mycobacteria in an effective concentration.

      • 1 Reply to fudfighter4
      • Started by Amy Leitman on 09 Oct 2012

        Philip Leitman is the publisher of NTM Info and Research.

        Obviously the market is beginning to catch on to the fact that arikace is not simply an orphan drug, but part of a drug platform that could eventually play a role in the multiple billion dollar pulmonary drug market. I have agreed from the first time you brought it up that there is no reason that I know why arikace would not be effective against MDR-TB. Government funding would of course be necessary, but world governments would spend plenty to eradicate TB.

        Did you read Budgies post earlier? There was never any other dog study with arikace, was there?

 
INSM
17.10Jul 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
El Pollo Loco Holdings, Inc.
NasdaqGSMon, Jul 28, 2014 4:00 PM EDT
Arrowhead Research Corp.
NasdaqGSMon, Jul 28, 2014 4:00 PM EDT
Sirius XM Holdings Inc.
NasdaqGSMon, Jul 28, 2014 4:00 PM EDT